COVID-19流行期间经PCR确诊的成年住院患者的生存分析及影响因素
Survival Analysis and Contributing Factors among PCR-Confirmed Adult Inpatients during the Endemic Phase of COVID-19.
作者信息
Benites-Godínez Verónica, Mendoza-Cano Oliver, Trujillo Xóchitl, Ríos-Silva Mónica, Lugo-Radillo Agustin, Bricio-Barrios Jaime Alberto, Cuevas-Arellano Herguin Benjamin, Ríos-Bracamontes Eder Fernando, Serrano-Moreno Walter, Cárdenas Yolitzy, Baltazar-Rodríguez Greta Mariana, Ortega-Ramírez Ana Daniela, Murillo-Zamora Efrén
机构信息
Coordinación de Educación en Salud, Instituto Mexicano del Seguro Social, Calzada del Ejercito Nacional 14, Tepic 63169, Mexico.
Unidad Académica de Medicina, Universidad Autónoma de Nayarit, Ciudad de la Cultura Amado Nervo, Tepic 63155, Mexico.
出版信息
Diseases. 2023 Sep 11;11(3):119. doi: 10.3390/diseases11030119.
In May 2023, the global health emergency status of COVID-19 concluded, marking the onset of an endemic era. This study assessed survival rates among PCR-confirmed adult inpatients during this phase and determined contributing factors. Employing a survival analysis approach, this investigation utilized a nationwide Mexican cohort encompassing 152 adult inpatients. Survival rates were computed using the Kaplan-Meier method, and a proportional Cox model identified mortality risk factors. Survival rates remained above 65% on day 14 after admission. Vaccination status, including the number of doses administered, was not significantly associated with fatal outcomes. Chronic kidney disease or a history of immunosuppression (due to any cause) increased mortality risk. Our findings underscore the persistent severity of COVID-19 beyond the global health emergency, emphasizing the necessity for tailored interventions for vulnerable patients.
2023年5月，新冠病毒病的全球卫生紧急状态结束，标志着大流行时代的开始。本研究评估了这一阶段经聚合酶链反应确诊的成年住院患者的生存率，并确定了相关影响因素。本调查采用生存分析方法，利用了一个涵盖152名成年住院患者的墨西哥全国队列。生存率采用Kaplan-Meier方法计算，比例风险模型确定了死亡风险因素。入院后第14天的生存率仍高于65%。疫苗接种状况，包括接种剂量数，与致命结局无显著关联。慢性肾病或免疫抑制病史（任何原因导致）会增加死亡风险。我们的研究结果强调了在全球卫生紧急状态结束后新冠病毒病的持续严重性，强调了针对脆弱患者采取针对性干预措施的必要性。
Zotero 插件